Correction to: Nature https://doi.org/10.1038/s41586-023-05707-3 Published online 22 February 2023

In the version of this article initially published, the Fig. 1 timeline was missing an entry for 2009: “CD19.BB.z-CAR shows enhanced anti-leukemic efficacy and prolonged survival in mouse xenograft models of primary human B-ALL (Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009))”. In Box 1, the “Cytokines: IL-18” entry was missing two references : Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025–3033 (2017) and Svoboda, J. et al. Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy. Blood 140, 4612–4614 (2022). The errors have been corrected in the HTML and PDF versions of the article.